India’s largest drug maker Sun Pharmaceutical Industries is getting ready to start the trials on a few drugs that have emerged as potential treatment candidates for Covid-19. This includes an anti-coagulant and anti-inflammatory drug nafamostat and another plant-based dengue drug candidate that Sun Pharma was developing along with government research institutes.
Sun Pharma stock was up 3.5 per cent on BSE on Friday.
On Friday, Sun Pharma said that it received the nod from the country’s drug regulator to initiate a clinical trial with nafamostat mesilate in Covid-19 patients. These will be phase II clinical trials on about 40 patients. This drug is approved in Japan for improvement of acute symptoms of pancreatitis as well as for treatment of DIC (Disseminated Intravascular Coagulation).
Basically, it is an anti-coagulant drug that has potential anti-inflammatory and anti-viral activities against Covid-19.
ALSO READ: Vodafone Idea